Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.
04.03.2025 13:43:59

EQS-Adhoc: Ad-hoc: CompuGroup Medical SE & Co. KGaA intends to reduce the annual dividend for the financial year 2024 to the legal minimum

EQS-Ad-hoc: CompuGroup Medical SE & Co. KGaA / Key word(s): Dividend
Ad-hoc: CompuGroup Medical SE & Co. KGaA intends to reduce the annual dividend for the financial year 2024 to the legal minimum

04-March-2025 / 13:43 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.


The general partner and the supervisory board of CompuGroup Medical SE & Co. KGaA (the „Company“) (ISIN: DE000A288904 | WKN: A28890) intend to propose to the annual general meeting that only the legally required minimum shall be paid out as dividend for the financial year 2024. This would result in a distribution of EUR 0.05 per dividend bearing share (previous year: EUR 1.00), assuming an unchanged amount of treasury shares. The proposal is made against the backdrop of the Company’s long-term innovation and growth strategy, including investments in infrastructure and resources for greater proximity to customers as well as AI-based processes and products. It further considers, based on the prepared consolidated financial statements, the development of revenue and profitability in the financial year 2024 in line with the adjusted full-year forecast.

According to the prepared consolidated financial statements, the Company generated revenues of approx. EUR 1.154 billion in the financial year 2024 (previous year: approx. EUR 1.188 billion). The organic revenue decreased by around two per cent year-on-year. Adjusted EBITDA decreased by around 15 per cent to approx. EUR 224.6 million (previous year: approx. EUR 264.8 million). The adjusted earnings per share amounted to approx. EUR 1.27 (previous year: approx. EUR 2.06).

A dividend payment based on the final dividend proposal of the general partner and the supervisory board for the financial year 2024 is subject to the approval by the annual general meeting, which is expected to be held in August 2025, as well as further legal requirements.

CompuGroup Medical SE & Co. KGaA will publish the full annual report for the financial year 2024 as planned on March 6, 2025.

“Adjusted EBITDA” and “adjusted earnings per share” are defined in the annual report for the financial year 2023 on p. 45 et seq.



End of Inside Information

04-March-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Germany
Phone: +49 (0)160 3630362
Fax: +49 (0)261 8000 3200
E-mail: investor@cgm.com
Internet: www.cgm.com
ISIN: DE000A288904
WKN: A28890
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2095063

 
End of Announcement EQS News Service

2095063  04-March-2025 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2095063&application_name=news&site_id=finanzen_net~~~069d1026-6a45-454f-953c-2a2c4451f1d6

Analysen zu CompuGroup Medical SE & Co. KGaA

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
18.03.25 CompuGroup Medical Buy Baader Bank
06.03.25 CompuGroup Medical Buy Baader Bank
24.02.25 CompuGroup Medical Buy Baader Bank
03.02.25 CompuGroup Medical Buy Baader Bank
13.01.25 CompuGroup Medical Hold Jefferies & Company Inc.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Investieren in Rüstungsaktien – Wall Street Live mit Tim Schäfer

Tim Schäfer analysiert im Gespräch mit David Kunz (COO der BX Swiss) die spannendsten Defense-Aktien aus Europa und den USA. Sind Rheinmetall, Palantir oder Lockheed Martin noch kaufenswert – oder schon überbewertet?
Wir sprechen über die Rolle von Trumps NATO-Druck, die massive Aufrüstung in Europa und warum gerade europäische Rüstungsaktien boomen.

✅ Top-Performer 2024
✅ Value- und Dividenden-Checks
✅ Geheimtipps wie BAE Systems, Thales & Co.
✅ Palantir als digitaler Profiteur

In unserem zweiwöchigen Format „Wall Street Live“ mit Tim Schäfer behandeln wir Topaktuelle Themen des Marktgeschehens.
🛑 Wichtig: Das Thema Rüstung ist gesellschaftlich wie ethisch komplex – in diesem Video beleuchten wir vor allem die börsentechnische Entwicklung und die wirtschaftlichen Auswirkungen globaler Ereignisse.

👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/

Investieren in Rüstungsaktien – Wall Street Live mit Tim Schäfer

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’200.00 11.76
Short 12’300.00 8.39
SMI-Kurs: 11’047.48 07.04.2025 17:31:08
Long 10’537.90 17.28 VSSM5U
Long 10’440.00 10.72
Long 9’904.19 8.78 3SSMKU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}